Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The RestLooking back on therapeutics stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Amgen (
NASDAQ:AMGN) and its peers. Over the ...
Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?The past six months have been a windfall for Moderna’s shareholders. The company’s stock price has jumped 46.4%, hitting $62.97 per share. This was partly th...
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid TumorsCAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (
NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic solid tumors. mRNA-4200 encodes for seven antigens commonly shared across patients and tumor types and is designed to help induce and expand T-cell responses against selected tumor targets.
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology StocksEarnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Natera (
NASDAQ:NTRA) and its ...
Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology StocksThe end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f...
Why Moderna (MRNA) Stock Is Trading Up TodayWhat Happened? Shares of biotechnology company Moderna (
NASDAQ:MRNA) jumped 2.6% in the afternoon session after the European Commission signed a contract to ...
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. (
NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second quarter 2026 financial results, and provide a corporate update.
Moderna Appoints Michael McDonnell to Board of DirectorsFormer Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience
